Evidence map›Paper›PMID 27775054›Full record

ArticleScientific reports2016

Thromboxane A2 receptor antagonist SQ29548 reduces ischemic stroke-induced microglia/macrophages activation and enrichment, and ameliorates brain injury.

Aijuan Yan, Tingting Zhang, Xiao Yang, Jiaxiang Shao, Ningzhen Fu, Fanxia Shen, Yi Fu, Weiliang Xia

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Microglia Polarization: A Novel Target of Exosome for Stroke Treatment.Frontiers in cell and developmental biology · 2022
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Revealing the Pharmacological Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Aijuan YanDepartment of Neurology &Institute of Neurology, Rui Jin Hospital, Shanghai Jiao Tong University, 200025, China.
Tingting ZhangSchool of Biomedical Engineering &Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200030, China.
Xiao YangSchool of Biomedical Engineering &Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200030, China.
Jiaxiang ShaoSchool of Biomedical Engineering &Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200030, China.
Ningzhen FuZhiyuan College, Shanghai Jiao Tong University, Shanghai, 200240, China.
Fanxia ShenDepartment of Neurology &Institute of Neurology, Rui Jin Hospital, Shanghai Jiao Tong University, 200025, China.
Yi FuDepartment of Neurology &Institute of Neurology, Rui Jin Hospital, Shanghai Jiao Tong University, 200025, China.
Weiliang XiaSchool of Biomedical Engineering &Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, 200030, China.
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thromboxane A2 receptor (TXA2R) activation is thought to be involved in thrombosis/hemostasis and inflammation responses. We have previously shown that TXA2R antagonist SQ29548 attenuates BV2 microglia activation by suppression of ERK pathway, but its effect is not tested in vivo. The present study aims to explore the role of TXA2R on microglia/macrophages activation after ischemia/reperfusion brain injury in mice. Adult male ICR mice underwent 90-min transient middle cerebral artery occlusion (tMCAO). Immediately and 24 h after reperfusion, SQ29548 was administered twice to the ipsilateral ventricle (10 μl, 2.6 μmol/ml, per dose). Cerebral infarction volume, inflammatory cytokines release and microglia/macrophages activation were measured using the cresyl violet method, quantitative polymerase chain reaction (qPCR), and immunofluorescence double staining, respectively. Expression of TXA2R was significantly increased in the ipsilateral brain tissue after ischemia/reperfusion, which was also found to co-localize with activated microglia/macrophages in the infarct area. Administration of SQ29548 inhibited microglia/macrophages activation and enrichment, including both M1 and M2 phenotypes, and attenuated ischemia-induced IL-1ß, IL-6, and TNF-α up-regulation and iNOS release. TXA2R antagonist SQ29548 inhibited ischemia-induced inflammatory response and furthermore reduced microglia/macrophages activation and ischemic/reperfusion brain injury.

Indexed as

Macrophage ActivationAnimalsBridged Bicyclo Compounds, HeterocyclicCytokinesDisease Models, AnimalFatty Acids, UnsaturatedGliosisHydrazinesMice, Inbred ICRReceptors, Thromboxane A2, Prostaglandin H2Reperfusion InjuryStrokeTreatment OutcomeBridged Bicyclo Compounds, HeterocyclicCytokinesFatty Acids, UnsaturatedHydrazinesReceptors, Thromboxane A2, Prostaglandin H2SQ 29548

Identifiers

PMID27775054
PMCPMC5075919
OpenAlexW2536128271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.